Precancerous lesions also known as cervical intraepithelial neoplasia check details (CIN) impose a health burden beyond that of CC itself, particularly in countries

with well-established screening programmes where CIN lesions are more likely to be detected [5]. High-grade cervical intraepithelial neoplasia (CIN2/3), when diagnosed, results in conisation or surgical excision to remove the lesion, as per consensus guidelines for management of CIN2/3 [6]. Vaccination against oncogenic HPV infection offers the potential for primary prevention of precancerous lesions and CC. Two HPV vaccines are currently available: a HPV-6/11/16/18 vaccine (Gardasil®, Merck/Sanofi-Pasteur) and a HPV-16/18 vaccine with Adjuvant System 04 (AS04) (Cervarix®, GlaxoSmithKline Vaccines). The PApilloma TRIal against Cancer In young Adults (PATRICIA) is the largest 3-Methyladenine mw trial conducted so far with a licenced

HPV vaccine. This trial assessing the HPV-16/18 AS04-adjuvanted vaccine enrolled 18,729 healthy women aged 15–25 years irrespective of their baseline HPV DNA status [7] and [8]. Data from the end-of-study analysis of the PATRICIA trial showed that the AS04-adjuvanted HPV-16/18 vaccine demonstrated 100% efficacy against CIN3+ lesions associated with HPV 16/18 and further had an overall vaccine efficacy (VE) of 93.2% against CIN3+ lesions irrespective

of HPV type in the HPV-naïve1 total vaccinated cohort (TVC) after a follow-up time up to 48 months [9]. These results demonstrated that protection against non-vaccine HPV types is present, with or without co-infection with HPV 16/18 [9] and [10]. These findings suggest that this vaccine could offer important health benefits in reducing precancerous lesions and CC cases beyond that expected from the prevention of lesions caused by HPV types-16/18 alone. The objective of the present study was to estimate the potential real life impact of the AS04-adjuvanted HPV-16/18 vaccine on CC cases and deaths at country crotamiton level in all WHO reported countries differentiating number of cases potentially prevented irrespective of the causative HPV type as well as cases prevented causally related to HPV-16/18. These number of cases and deaths were subsequently grouped by continent. Additionally, potential reduction in the treatment costs of CC in five countries located in five different regions and the potential effect of vaccination on the burden and cost of precancerous lesions in two other countries (one from Europe and one from Asia) was evaluated.